Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2004-05-27
2010-12-14
O'Sullivan, Peter G (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S529000, C514S547000, C514S642000, C560S001000, C560S196000, C560S250000, C560S251000, C560S253000, C564S291000, C564S293000
Reexamination Certificate
active
07851505
ABSTRACT:
The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4430443 (1984-02-01), Seiver
patent: 4765539 (1988-08-01), Noakes et al.
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van der Linden et al.
patent: 6703050 (2004-03-01), Brewer et al.
patent: 7189865 (2007-03-01), Ternansky et al.
patent: 2004/0259945 (2004-12-01), Brewer et al.
patent: 2005/0058720 (2005-03-01), Brewer et al.
patent: 2006/0148891 (2006-07-01), Ternansky et al.
patent: WO 00/13712 (2000-03-01), None
patent: WO 2004/009034 (2004-01-01), None
patent: WO 2004/009072 (2004-01-01), None
patent: WO 2005/082382 (2005-09-01), None
Adelman et al., 1983, “In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone.” DNA 2:183-193.
Bajou et al., 1998, “Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.” Nat. Med. 4:923-928.
Bamba et al., 1979 “Release Mechanisms in Gel-forming Sustained Release Preparations.” Int. J. Pharrn 2, 307.
Benjamin et al., 1999, “Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.” J. Clin. Invest 103:159-165.
Blood et al., 1990, “Tumor interactions with the vasculature: angiogenesis and tumor metastasis.” Biochem. Biophys, Acta. 1032: 89-118.
Borgstrom et al., 1998, “Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.” Prostrate 35:1-10.
Brem et al., 1990, “Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain.” Neurosurgery. 26:391-396.
Brem et al., 1990, “Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.” Am. J. Pathol. 137(5):1121-1142.
Brown, 2001, “Copper and Prion disease.” Brain Res. Bull 55:165-173.
Brown, 2002, “Copper and Prion disease.” Biochem. Soc. Tras. 30:742-745.
Carri et al., 2001, “Copper-dependent oxidative stress, alteration of signal transduction and neurodegeneration in amyotrophic lateral sclerosis.” Funct. Neurol. 16:181-188.
Chakravarty et al., 1984, “Serum copper in malignant neoplasia with special reference to the cervix uteri.” J. Cancer Res. Clin. Oncol. 108:312-315.
Chambers et al., 1995, “Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.” Canc. Res. 55:1578-1585.
Chen et al., 2002, “TNF-R1 signaling: A beautiful Pathway.” Science 296:1634-5.
Crowley et al., 1993, “Prevention of Metastasis by Inhibition of the Urokinase Receptor” Proc. Natl. Acad. Sci. USA 90: 5021-5025.
During et al., 1989, “Controlled Release of Dopamine from Polymeric Brain Implant: In Vivo Characterization.” Ann. Neurol. 25:351.
Folkman, 1972, “Anti-angiogenesis: new concept for therapy of solid tumors.” Ann. Surg. 175: 409-416.
Folkman, 1995, “Angiogenesis inhibitors generated by tumors.” Mol. Med 1(2): 120-122.
Folkman, 1995, “The influence of angiogenesis research on management of patients with breast cancer.” Breast Cancer Res. Treat. 36(2): 109-118.
Gnjec et al., 2002, “Transition metal chelator therapy—a potential treatment for Alzheimer's disease.” Front. Biosci 7:1016-23.
Goodson, 1984, “Medical Applications of Controlled Release.” vol. 2, Chapt. 6, 115-138.
Gorelik et al., 1980, “Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity.” J. Nat'l. Canc. Inst. 65:1257-1264.
Gorelik et al., 1980, “Host's immune state and kinetics of local tumor growth control—progression of postoperative lung metastasis.” Rec. Results Canc. Res. 75:20-28.
Gullino, 1986, “Considerations on the mechanism of the angiogenic response.” Anticancer Res. 6(2):153-158.
Hanada et al., 2002, “Regulation of cytokine signaling and inflammation.” Cytokine Growth Factor Rev. 13:413-421.
Hanahan et al., 1996, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.” Cell 86(3): 353-364.
Harrison et al., 1971-1996, “Compendium of Synthetic Organic Methods.” vols. 1-8 John Wiley & Sons.
Hilgard et al., 1977, “Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL)”, Br. J. Cancer 35:78-86.
Howard et al., 1989, “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficit.” J. Neurosurg., 71:105.
Isakov et al., 1982, “An immune response against the alloantigens fo the 3LL Lewis lung carcinoma prevents the growth of lung metastases, but not of local allografts.” Invasion Metas. 2:12-32.
Kleinman et al., 1986, “Basement membrane complexes with biological activity.” Biochemistry, 25: 312-318.
Koch et al., 1992, “Interleukin-8 as a macrophage-derived mediator of angiogenesis.” Science 258:1798-801.
Kowalik-Jankowska et al., 2002, “Possible involvement of copper(II) in Alzheimer disease.” Environ Health Perspect 5:869-870.
Langer, “New methods of drug delivery.” Science 1990, 249:1527-1533.
Levy et al., 1985, “Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate.” Science 228: 190.
Llanos et al., 2002, “The molecular basis of copper homeostasis copper-related disorders.” DNA Cell Biol. 21:259-270.
Loskutoff et al., 2000, “The fat Mouse: A powerful Genetic Model to Study Hemostatit Gene Expression in Obesity/NIDDM.” Ann. N.Y. Acad Sci. 902:272-281.
Malave et al., 1979, “Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice.” J. Nat'l. Canc. Inst. 62:83-88.
Maynard et al., 2002, “Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron.” J. Biol. Chem 277: 44670-44676.
McDonald et al, 1983, “Syntheses and characterization of ammonium and tetraalkylammonium thiomolybdates and thiotungstates.” Inorg Chim. Acta 72:205-210.
Merajver et al., 1998, “Cooper Depletion as and Anti-Angiogenic Strategy in HER2-neu Transgenic.” Proceedings of Special AACR Conference on,Angiogenesis and Cancer, Abstract #B-11, Jan. 22-24.
Millauer et al., 1996, “Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.” Cancer Res. 56: 1615-1620.
Min et al., 1996, “Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.” Cancer Res. 56: 2428-2433.
Miyake et al., 2000, “Transforming growth factor-beta1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integ
Allan Amy L.
Gladstone Patricia L.
Mazar Andrew
Price Melissa L. P.
Ternansky Robert J.
Attenuon, LLC
Jones Day
O'Sullivan Peter G
LandOfFree
Thiotungstate analogues and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiotungstate analogues and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiotungstate analogues and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237946